A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

March 9, 2022 updated by: Bristol-Myers Squibb

A Phase 1 Study of the Safety and Pharmacokinetics of Anti-KIR Monoclonal Antibody (Lirilumab, BMS-986015) in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab,BMS-936558) or in Combination With Nivolumab and Anti-CTLA-4 Monoclonal Antibody (Ipilimumab, BMS-734016) in Advanced and/or Metastatic Solid Tumors

The purpose of this study is to determine whether lirilumab in combination with nivolumab or in combination with nivolumab and ipilimumab is safe in the treatment of advanced and/or metastatic solid tumors

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
10

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Japan
    • Chiba
      • Kashiwa-shi, Chiba, Japan, 2778577
        • Local Institution
    • Hyogo
      • Kobe-shi, Hyogo, Japan, 6500017
        • Local Institution

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

  • Participants must have histologic or cytologic confirmation of a solid malignancy that is advanced (metastatic and/or unresectable)
  • Presence of at least 1 lesion with measurable disease as defined by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) criteria for response assessment
  • The Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

  • Participants with untreated central nervous system (CNS) metastases
  • Participants with an active, known, or suspected autoimmune disease
  • Uncontrolled or significant cardiovascular disease

Other protocol defined inclusion/exclusion criteria could apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Part One Combination Therapy
Lirilumab and Nivolumab
Biological: Nivolumab
Specified dose on specified days
Other Names:
  • BMS-936558
  • Opdivo
Biological: Lirilumab
Specified dose on specified days
Other Names:
  • BMS-986015
Experimental: Part 2 Combination Therapy
Lirilumab, Nivolumab and Ipilimumab
Biological: Nivolumab
Specified dose on specified days
Other Names:
  • BMS-936558
  • Opdivo
Biological: Ipilimumab
Specified dose on specified days
Other Names:
  • BMS-734016
  • Yervoy
Biological: Lirilumab
Specified dose on specified days
Other Names:
  • BMS-986015

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Incidence of dose-limiting toxicity (DLT)
Time Frame: Up to two years
To assess the safety and tolerability of lirilumab in combination with nivolumab
Up to two years
Incidence of adverse events (AEs)
Time Frame: Up to two years
To assess the safety and tolerability of lirilumab in combination with nivolumab
Up to two years
Incidence of serious adverse events (SAEs)
Time Frame: Up to two years
To assess the safety and tolerability of lirilumab in combination with nivolumab
Up to two years
Incidence of death
Time Frame: Up to two years
To assess the safety and tolerability of lirilumab in combination with nivolumab
Up to two years
Frequency of laboratory test toxicity grade shifting from baseline
Time Frame: Up to two years
To assess the safety and tolerability of lirilumab in combination with nivolumab
Up to two years
Incidence of AEs leading to discontinuation
Time Frame: Up to two years
To assess the safety and tolerability of lirilumab in combination with nivolumab
Up to two years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Incidence of dose-limiting toxicity (DLT)
Time Frame: Up to two years
To assess the safety and tolerability of lirilumab in combination with nivolumab and ipilimumab
Up to two years
Incidence of adverse events (AEs)
Time Frame: Up to two years
To assess the safety and tolerability of lirilumab in combination with nivolumab and ipilimumab
Up to two years
Incidence of serious adverse events (SAEs)
Time Frame: Up to two years
To assess the safety and tolerability of lirilumab in combination with nivolumab and ipilimumab
Up to two years
Incidence of death
Time Frame: Up to two years
To assess the safety and tolerability of lirilumab in combination with nivolumab and ipilimumab
Up to two years
Frequency of laboratory test toxicity grade shifting from baseline
Time Frame: Up to two years
To assess the safety and tolerability of lirilumab in combination with nivolumab and ipilimumab
Up to two years
Maximum serum observed concentration (Cmax)
Time Frame: Up to two years
To characterize the Pharmacokinetic (PK) of lirilumab given in combination with nivolumab
Up to two years
Time of maximum observed serum concentration (Tmax)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab
Up to two years
Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration [AUC(0-T)]
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab
Up to two years
Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab
Up to two years
Trough observed serum concentration (Ctrough)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab
Up to two years
Area under the serum concentration-time curve in one dosing interval [AUC(TAU)]
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab
Up to two years
Clearance (CL)
Time Frame: Up to two years
To characterize the PK and immunogenicity of lirilumab given in combination with nivolumab
Up to two years
Volume of distribution at steady state (Vss)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab
Up to two years
Ratio of an exposure measure at steady-state to that after the first dose (AI)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab
Up to two years
Half-life (T-HALF)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab
Up to two years
Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALF eff)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab
Up to two years
Best overall response (BOR)
Time Frame: Up to two years
To assess the preliminary anti-tumor activity
Up to two years
Duration of response (DOR)
Time Frame: Up to two years
To assess the preliminary anti-tumor activity
Up to two years
Incidence of anti-drug antibody (ADA)
Time Frame: Up to two years
To characterize immunogenicity
Up to two years
Incidence of AEs leading to discontinuation
Time Frame: Up to two years
To assess the safety and tolerability of lirilumab in combination with nivolumab and ipilimumab
Up to two years
Maximum serum observed concentration (Cmax)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab
Up to two years
Time of maximum observed serum concentration (Tmax)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab
Up to two years
Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration [AUC(0-T)]
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab
Up to two years
Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab
Up to two years
Trough observed serum concentration (Ctrough)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab
Up to two years
Area under the serum concentration-time curve in one dosing interval [AUC(TAU)]
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab
Up to two years
Clearance (CL)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab
Up to two years
Volume of distribution at steady state (Vss)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab
Up to two years
Ratio of an exposure measure at steady-state to that after the first dose (AI)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab
Up to two years
Half-life (T-HALF)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab
Up to two years
Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALF eff)
Time Frame: Up to two years
To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab
Up to two years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bristol-Myers Squibb

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Ono Pharmaceutical Co. Ltd

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 14, 2017

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 6, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 6, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 28, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 28, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 29, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 10, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 9, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CA223-030

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Advanced Cancer

Clinical Trials on Nivolumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings